Treatment of central sleep apnoea in congestive heart failure with nasal ventilation

G N Willson, I Wilcox, A J Piper, W E Flynn, R R Grunstein, C E Sullivan

Cheyne-Stokes respiration (CSR) is common in patients with congestive heart failure (CHF). This characteristic crescendo-decrescendo pattern of breathing is often seen during sleep in patients with CHF and is a form of central sleep apnoea. Disordered nocturnal breathing leads to oxygen desaturation, poor sleep quality, and altered sleep architecture. These features may lead to complaints of daytime somnolence, fatigue, insomnia, and many of the symptoms typical of sleep disordered breathing.

It has been proposed that CSR during sleep in patients with heart failure is an indicator of a poor prognosis. The likely adverse effects of CSR on daytime performance and myocardial function have resulted in the introduction and led study nCPAP was shown to improve both sleep quality and daytime myocardial function. Other groups have found nCPAP to be ineffective in controlling CSR.

Nocturnal nasal intermittent positive pressure ventilation (nIPPV) is the accepted treatment for patients with chronic respiratory failure due to hypoventilation during sleep. We hypothesised that nIPPV may also effectively treat central sleep apnoea in heart failure by controlling ventilation and carbon dioxide in patients whose disordered breathing has been linked to fluctuating carbon dioxide levels, relative hyperventilation, and hypocapnia. Nasal IPPV was administered in an attempt to mechanically ventilate the patient through the apnoeic portion of the Cheyne-Stokes cycle, thereby preventing fluctuations in carbon dioxide levels and consequently abolishing CSR.

This study describes the use of nocturnal nIPPV in a group of patients with heart failure and Cheyne-Stokes respiration during sleep. The effects of this therapy on respiratory disturbance and sleep quality following an in-hospital acclimatisation period are reported. We also report our experience with long term domiciliary therapy and its effects on daytime left ventricular function in patients who remained compliant with treatment.

Methods

PATIENT SELECTION
All patients referred to our centre in the period October 1993 to January 1996 were assessed for the study. Patients with moderate to severe stable chronic left ventricular heart failure were included. All subjects had documented severe repetitive central sleep apnoea (respiratory disturbance index, RDI >30/h) and minimal obstructive apnoea (<10% of respiratory events). Patients were excluded if they had been admitted to hospital or changed their medication within one month of the study or if they were unable to tolerate a nasal mask (one patient). They were also excluded if there was a history of completed stroke or significant pulmonary disease. All patients consented to participate in the study and the protocol was approved by the ethics committee of our institution.

All patients were examined by a cardiologist to confirm both historical and clinical evidence of chronic heart failure. Subjects had measurements of anthropometric variables (height/weight), awake arterial blood gas tensions, and left ventricular ejection fraction (LVEF) using radionuclide gated blood pool scanning with technetium-99 pertechnetate. The radionuclide studies were performed using the standard clinical protocol and reported by a physician who was blinded to the treatment status of the patient and the likely effects of nIPPV.

The subjects continued to take their normal cardiac medications throughout the period of the study. These medications were converting enzyme inhibitor (10 patients), diuretic (10 patients), digoxin (seven patients), amiodarone (two patients), long acting nitrates (three patients), calcium antagonist (one patient). No patient who took part in the analysis of sleep was taking any hypnotic or antidepressant medication.

SLEEP STUDIES
All patients had overnight full sleep studies whilst breathing room air. Studies were conducted between 21.00 hours and 07.30 hours. Sleep state was monitored using standard techniques. Breathing variables which were monitored included chest wall and abdominal motion, diaphragm electromyogram (EMGd), arterial oxyhaemoglobin saturation (SaO2), transcutaneous carbon dioxide pressure (PtCO2), and nasal airflow. Electrocardiograms were measured continuously in all patients. All variables were recorded on a 16 channel polygraph.

Sleep stages were scored according to standard criteria and expressed as a percentage of total sleep time (TST). Sleep efficiency was defined as the percentage of the total recording time which was scored as sleep. Arousal was defined as an awakening for longer than three seconds.

Apnoeas and hypopnoeas were scored according to standard criteria as previously described. Obstructive events whilst receiving nIPPV were scored in the presence of desaturation and...
arousal preceded by a transient period of increased peak inspiratory airway pressures.

INITIATION OF NASAL IPPV
Following the confirmation of the diagnosis of CSR in sleep, 11 patients were acclimatised to nasal ventilation. All patients used commercially available masks and head straps (Sullivan™, ResMed Inc, Sydney, Australia). A volume preset ventilator (PV 201, Breas, Goteborg, Sweden) was used to deliver room air whilst allowing the setting of tidal volume, breath rate, and inspiratory time. The aim of the titration protocol was to control CSR by providing mechanical ventilation. Breath rate and inspiratory time were set in such a way as to match the patient’s awake breathing pattern, while tidal volume was set so that PtcCO2 was maintained at or slightly below the patient’s awake level (0.1–0.4 kPa). All patients needed a chin strap to prevent or minimise mouth leaks. Positive end expiratory pressure (PEEP) was applied to the expiratory valve if upper airway obstruction was present. Nasal ventilation was commenced on an inpatient basis, with the patient acclimatising to the device during daytime practice sessions and then gradually increasing the hours the machine was used at night. Over the first three days all patients were monitored continuously during sleep with both SaO2 and PtcCO2 to ensure the safety and efficacy of ventilation. Once acclimatised to the device, a repeat full sleep study on nIPPV was performed to ensure the adequacy of ventilation and to gauge the effect of treatment on both apnoea and sleep quality.

Seven patients underwent a third full sleep study off nIPPV following a period of domiciliary therapy. The purpose of this study was to assess the effect of nIPPV withdrawal on sleep disordered breathing.

DOMICILIARY THERAPY
All 11 patients were commenced on a home trial of nIPPV. The aim of this trial was to use nIPPV for at least a three month period and then to re-evaluate both subjective and objective responses to treatment. Repeat measures of LVEF were made in the seven patients who continued on treatment for at least one month. The most recent measure of cardiac function whilst on nIPPV was compared with baseline.

STATISTICAL ANALYSIS
All values are shown as mean (SD) unless stated otherwise. In the seven patients who had all three sleep studies we tested for an effect of treatment on respiratory disturbance, sleep fragmentation, and sleep architecture using two way repeated measures ANOVA followed by planned linear comparisons of ventilation night versus the mean of the two diagnostic nights and the difference between the two diagnostic nights. The changes in sleep variables from diagnostic to nIPPV nights and changes in LVEF were compared using paired Student’s t tests.

Results

PATIENTS
Eleven men with CHF and CSR during sleep were commenced on nIPPV. All patients continued with a domiciliary trial of the device. Ten patients were included in the analysis of nIPPV on sleep, one patient who received a short period of nCPAP during his diagnostic study being excluded from this part of the analysis. Seven patients underwent a repeat full sleep study off nIPPV. This repeat study was performed after a median (interquartile range) of 36 (28–78) nights on nIPPV.

Patients were referred from a variety of sources. Seven patients had undergone previous sleep studies with four having failed a treatment trial with nCPAP due to either poor compliance or inadequate therapeutic response. Referrals from both respiratory physicians and cardiologists directly to our sleep unit accounted for the remaining four patients. All subjects had symptoms of sleep apnoea syndrome with either a history of excessive daytime somnolence or witnessed apnoeas.

The patients’ baseline clinical characteristics are shown in table 1 including anthropometric data, New York Heart Association (NYHA) functional class, LVEF, body mass index (BMI), and arterial blood gas tensions. The mean (SD) age of the patients was 70 (11) years (range 47–83). Patients were mostly non-obese with a mean BMI of 26.7 (4.6) kg/m2, the highest being 32.8 kg/m2. Left ventricular function was predominantly at least moderately impaired with an LVEF of 23 (9)% (range 11–40%). The group as a whole had Pco2,
values at the lower end of the normal range with a mean value of 5.0 (0.5) kPa.

SLEEP STUDIES

The diagnostic sleep study demonstrated that all patients had significant central sleep apnoea with a mean RDI of 54.14 events/h and a minimum SaO₂ of 77.5% (5%). Apnoeic events were predominantly central in nature with a Cheyne-Stokes pattern. Seven patients had some degree of partial upper airway obstruction which was evidenced by either snoring (n = 2) or partial obstruction (n = 7), identified by airflow notching during the period of hyperpnoea following central apnoea. The mean interval between the commencement of ventilation and the repeat sleep study was 4.2 days (range 1–7).

The use of nIPPV during sleep abolished CSR in all patients with a reduction in the RDI to 5.0 events/h (p <0.001; fig 1). Residual events were due to upper airway obstruction. There was a marked reduction in the total number of arousals from 48.14 to 14.6 events/h (p <0.001), whilst arousals due to non-respiratory causes increased when using nIPPV (8.6 versus 13.5 events/h, p <0.01; fig 2). Patient 11 had a similar response to the group as a whole with a marked reduction in RDI from 54 (time on CPAP excluded) to 4 events/h.

The TST and sleep efficiency were unaffected by the introduction of nIPPV. Sleep architecture was modified by nIPPV with a significant reduction in stage 1/2 sleep (8.2% during control versus 64.16% during nIPPV, p <0.01) and an increase in slow wave sleep (6.6% during control versus 19.17% during nIPPV, p <0.05; fig 3). There was a small but non-significant increase in REM sleep from 13 (6) to 19 (6) events/h (p = 0.08; fig 3).

Table 2 summarises the sleep study data for the seven patients who underwent a repeat sleep study off nIPPV. No significant difference was noted in any of the sleep related variables between the initial study and the study off nIPPV.

During the night of treatment with nIPPV the PtcCO₂ (mean of the first 10 minutes of stable stage 1/2 sleep) fell slightly from 5.78 (0.82) to 5.48 (0.51) kPa in nine patients (data from three patients not reported due to technical difficulties). Arterial blood gas tensions were measured on awakening in six patients. There was little change in pH (7.41 (0.02) in the afternoon versus 7.42 (0.06) on awakening) or in PaCO₂ (5.16 (0.49) kPa in the afternoon versus 4.96 (0.35) kPa on awakening).

ACCLIMATISATION TO NASAL IPPV

Most of the subjects adapted quickly to the ventilator and slept with the machine for a mean of 3.9 hours (range 1.5–6.75) on the first night. Ventilator settings used included a mean breath rate of 17/min (range 14–19), a mean tidal volume of 0.86 l (range 0.75–1.00), and a mean inspiratory time of 1.4 s (range 1.2–1.5). These settings resulted in peak pressures in the range of 15–20 cm H₂O during effective ventilation in the absence of leaking. Two patients required 5 cm H₂O of PEEP to eliminate airway obstruction; no end expiratory pressure was used in the remaining nine patients.

Nasal IPPV was well tolerated by all patients whilst in hospital. All patients reported an improvement in their symptoms of excessive daytime sleepiness. A subjective improvement in exercise tolerance was reported in all but one patient. Complications of nIPPV were minor and included abdominal bloating in one patient, which was treated with the ingestion of
peppermint water before sleep. Three patients found the chinstrap uncomfortable. Patients required a period of 7.3 days (range 2–11 days) to become completely comfortable sleeping with the machine and to be proficient in mask fitting and adjustment so as to undertake self-administered domiciliary care.

DOMICILIARY EXPERIENCE
Six of the 11 patients completed the three month trial. Three patients stopped using the device, one due to domestic difficulties, one due to cough associated with pneumonia, and one because of problems with sleep initiation. Two patients died during the course of the study, one at one month due to a pneumonia following a stroke and the second at one month from cardiac arrest while awake during the day, the likely cause being a primary cardiac arrhythmia. Neither patient had experienced a worsening of cardiac failure whilst using nIPPV. The patient who died following a cardiac arrest had been reviewed the previous day. At that time he was subjectively well with reports of increased exercise tolerance matched by an objective improvement in LVEF from 11% to 23%. One patient required readmission during the course of the domiciliary trial because of worsening of heart failure. He responded well to a short term increase in his diuretic therapy and was discharged on his previous medications.

LEFT VENTRICULAR EJECTION FRACTION (LVEF)
LVEF increased from 25 (9)% to 31 (10)% (p <0.05) in the seven patients who continued to use the device for at least one month (five of these seven patients had used nIPPV for at least three months). Figure 4 shows the individual patient data and illustrates that the response to treatment was variable with only three patients showing an improvement in LVEF of >6%. Only one patient had a lower LVEF at the repeat study (from 27% to 24%). In the three non-compliant patients only one had LVEF repeated which changed little (from 22% to 20%). One patient died before a follow up measurement of LVEF was made.

Discussion
This study documents our experience with nIPPV in patients with chronic heart failure and central sleep apnoea. We have shown that CSR during sleep can be abolished with the use of nIPPV. Nasal ventilation leads to improved sleep architecture with a reduction in arousals and a fall in RDI. LVEF was improved in the compliant patients. Further studies are required to determine whether these improvements translate into clinical benefit.

Table 2  Mean (SD) sleep study data

<table>
<thead>
<tr>
<th></th>
<th>Diagnostic study (n=7)</th>
<th>nIPPV (n=7)</th>
<th>Off nIPPV (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total sleep time (min)</td>
<td>256 (73)</td>
<td>269 (61)</td>
<td>251 (91)</td>
</tr>
<tr>
<td>Sleep efficiency (%)</td>
<td>63 (17)</td>
<td>64 (10)</td>
<td>61 (23)</td>
</tr>
<tr>
<td>Stage 1/2 (% TST)</td>
<td>80 (10)</td>
<td>63 (10)</td>
<td>82 (17)</td>
</tr>
<tr>
<td>Slow wave sleep (% TST)</td>
<td>7 (7)</td>
<td>18 (11)</td>
<td>7 (7)</td>
</tr>
<tr>
<td>REM (% TST)</td>
<td>14 (7)</td>
<td>19 (6)</td>
<td>12 (10)</td>
</tr>
<tr>
<td>RDI (events/h)</td>
<td>54 (16)</td>
<td>6 (6)*</td>
<td>53 (20)</td>
</tr>
<tr>
<td>Minimum Sao2 (%)</td>
<td>77 (5)</td>
<td>85 (3)*</td>
<td>78 (5)</td>
</tr>
<tr>
<td>Arousal index (arousals/h)</td>
<td>46 (13)</td>
<td>15 (6)*</td>
<td>37 (15)</td>
</tr>
<tr>
<td>Non-respiratory arousals (arousals/h)</td>
<td>7 (4)</td>
<td>14 (3)*</td>
<td>5 (3)</td>
</tr>
</tbody>
</table>

*p<0.01; †p<0.05 (two way ANOVA).

nIPPV = nasal intermittent positive pressure ventilation; TST = total sleep time, REM = rapid eye movement sleep; RDI = respiratory disturbance index; Sao2 = oxyhaemoglobin saturation.

Figure 3  (A) Total sleep time; (B) stage 1/2 sleep; (C) slow wave sleep; (D) REM sleep. Dx = baseline diagnostic; nIPPV = on nIPPV; Dx2 = repeat study off nIPPV.

Figure 4  Change in LVEF with nIPPV.
Treatment of central sleep apnoea in congestive heart failure with nasal ventilation

S45

Sleep architecture with a reduction in the arousal index, a decrease in stage 1/2 sleep, and a significant increase in slow wave sleep. Although nasal ventilation was well tolerated by all patients whilst in hospital, compliance decreased markedly in the home environment. Nevertheless, those patients who continued to use the device on a regular basis reported an improvement in symptoms of daytime somnolence, fatigue, and breathlessness. Nasal IPPV was associated with an increase in LVEF in these patients.

Nasal IPPV is an effective treatment for patients with chronic respiratory failure due to neuromuscular disease and chest wall abnormalities. The mechanism of improvement in these patients is thought to be due to reversal of nocturnal hypoventilation by mechanical ventilation. Many patients with hypercapnic respiratory failure exhibit nocturnal hypoventilation and central apnoea which is well controlled with nIPPV. This study demonstrates that the use of this modality of treatment can be extended to patients with central sleep apnoea due to congestive heart failure.

We hypothesised that nIPPV could be used to support ventilation during the apnoeic portion of the Cheyne-Stokes cycle, preventing alterations in blood gas tensions and thereby preventing arousal associated with these apnoeas. In fact, in many of our patients no spontaneous breathing effort was seen during ventilation, presumably because the arterial carbon dioxide tension was below the apnoeic threshold during sleep. This mechanism differs markedly from that of nCPAP which has been shown to decrease central respiratory events by increasing arterial carbon dioxide tension, reducing the unstable respiratory control induced by hypocapnia.

The most significant finding of this study is the abolition of CSR during sleep using nIPPV. Reductions in RDI have been reported with the use of both supplemental oxygen and nCPAP. Hanley et al reported a reduction in the apnoea/hypopnoea index (AHI) from 30 (4.7) to 18.9 (2.4) events/h whilst breathing supplemental oxygen. Naughton et al found a decrease in AHI from 43.2 (4.9) to 14.7 (4.8) events/h on nCPAP following one month of domiciliary use. This finding is in contrast to the reports of Buckle et al, Guilleminault et al, and Davies et al who showed no improvement in apnoea indices in shorter trials of CPAP. A number of explanations have been proposed for the conflicting results on CPAP including the prescription of inadequate pressures or the failure of an adequate acclimatisation period. The results of the present study show that effective treatment of severe CSR is possible following a short period of acclimatisation.

Residual respiratory events on nIPPV were due to obstructive events predominantly at sleep onset. The addition of PEEP at 5 cm H2O in two patients decreased the number of these events, although intermittent mouth leaking makes the continuous maintenance of this PEEP almost impossible. These obstructive episodes are not surprising given that a number of authors have commented on the likely role of upper airway closure in the pathogenesis of central sleep apnoea.

Sleep fragmentation has been reported as a dominant feature of sleep in patients with CSR and CHF, with arousal usually occurring at the peak of the hyperpnoea. Arousal indices were markedly reduced on nIPPV from 48.3 to 13.8 (5.7) events/h. Indeed, the number of arousals on the nIPPV night was similar to that in normal subjects sleeping in our laboratory and below that found by other authors. A marked reduction in numbers of arousals occurred despite an increase in disturbance due to non-respiratory events, presumably from the device itself. A reduction in arousal index has also been reported with the use of oxygen (from 30 (4.7) to 13.8 (1.9) events/h). Studies using nCPAP have reported conflicting results. Naughton et al reported an improvement in one study (from 35.5 (5.5) to 23.5 (4.4) events/h) whereas in two subsequent studies the improvement in arousal indices was non-significant. The reason for the improved effectiveness of nIPPV in the reduction of arousals is probably due to the greater control of CSR this treatment affords.

Abnormal sleep architecture with a reduction in the amount of slow wave sleep is a consistent finding in patients with CSR. Nasal IPPV resulted in an improvement in sleep architecture with a significant decrease in stage 1/2 sleep and an increase in slow wave sleep. Both supplemental oxygen and nCPAP result in a reduction in stage 1/2 sleep but changes in slow wave sleep were not reported using oxygen and have only been reported in one study using nCPAP. We believe the increase in slow wave sleep on nIPPV may reflect the more effective control of apnoea, therefore permitting transition into deeper stages of sleep. There was a trend towards an increase in the amount of REM sleep during nIPPV, but this did not reach statistical significance. This may be due to the small number of patients and the fact that most of the patients had a low apnoea index in REM sleep during spontaneous breathing.

The sleep studies off nIPPV showed that chronic nIPPV does not appreciably change the underlying breathing disorder in patients with severe central sleep apnoea. The study off nIPPV confirms that nIPPV is responsible for the observed reduction in respiratory events and improvement in sleep quality. No significant difference was found between the initial and repeat diagnostic studies for any of the measured variables. The repeat diagnostic studies showed that the changes observed were due to nIPPV and not related to either night-to-night variability or acclimatisation to the laboratory.

We showed an improvement in LVEF in seven patients previously stable on medical treatment who continued to use nIPPV for at least one month. Naughton et al have shown improvement in LVEF following three months of nCPAP, with this result being confirmed in subsequent studies from the same group. The clinical significance of the observed
improvement in LVEF in our study is difficult to determine in an uncontrolled study using such small numbers. The LVEF itself is a measure which is subject to a large amount of spontaneous variability in chronic heart failure.26 The present study only reports the results of patients compliant with nIPPV. A controlled study with a large number of subjects would be required to determine whether a significant improvement in cardiac function had occurred, and if this change was significant using an intention to treat analysis.

We believe the role of nIPPV will be to complement the existing therapies for CSR in heart failure. In patients who have an inadequate therapeutics response or fail to tolerate nCPAP, nIPPV is a realistic alternative treatment modality. We believe that nasal ventilation is best applied by a highly trained therapist who can adjust machine settings to maintain patient comfort whilst achieving the desired ventilatory aims. In this study ventilation was commenced whilst the subject was an inpatient in hospital, allowing time for an extensive programme of education and acclimatisation. Four patients who had previously used nCPAP all commented on the increased comfort of nasal ventilation, with reports of improved sleep quality on nIPPV.

Long term domiciliary usage of the device was poor with only six of the 11 patients completing the three month trial. Three subjects stopped using nIPPV for the reasons outlined earlier. The two patients who died during the course of the study did so for reasons which were unrelated to their treatment. CHF is associated with a high risk of cardiac death (due to progressive heart failure or sudden death) and stroke. Five patients continue to use nasal ventilation long term and another has transferred to nCPAP. Two patients have continued treatment for more than two years and these patients are extremely reluctant to sleep without using nIPPV.

In summary, nasal ventilation can abolish Cheyne-Stokes respiration during sleep in patients with chronic heart failure. Abolition of CSR was associated with improvement in both sleep quality and symptoms of daytime somnolence, fatigue, and breathlessness. In those patients who continued to use the device at home, improvement in LVEF was documented. Further long term controlled studies are required to clarify the role of domiciliary therapy and to investigate the utility of nIPPV in comparison with existing therapies for central sleep apnoea during sleep.

The authors are grateful to the medical and nursing staff of the Centre for Respiratory Failure and Sleep Disorders, Royal Prince Alfred Hospital, for their practical assistance. We thank Michael Berthon-Jones and Stephen McNamara for helpful statistical advice. Supported by Medical Gases Australia and a project grant from the National Health and Medical Research Council of Australia.

Treatment of central sleep apnoea in congestive heart failure with nasal ventilation

G N Willson, I Wilcox, A J Piper, W E Flynn, R R Grunstein and C E Sullivan

Thorax 1998 53: S41-S46
doi: 10.1136/thx.53.2008.S41

Updated information and services can be found at:
http://thorax.bmj.com/content/53/suppl_3/S41

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Airway biology (1100)
Heart failure (27)
Sleep disorders (132)
Sleep disorders (neurology) (199)
Sleep disorders (respiratory medicine) (199)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/